On Tuesday, salesforce.com, inc. (NYSE:CRM)’s shares declined -0.274% to $72.92.
salesforce.com, inc. (NYSE:CRM) declared the company’s annual meeting of stockholders will be held on Thursday, Jun. 4, 2015 at 2:00 p.m. (PDT) / 5:00 p.m. (EDT). The meeting will be held at Salesforce, located at 50 Fremont Street, San Francisco, California 94105. Stockholders are invited to attend the meeting and should refer to Salesforce’s proxy statement accessible at www.salesforce.com/investor for details regarding required documentation to gain admission to the meeting.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide. The company offers enterprise cloud computing apps and platform services, counting Sales Cloud for sales force automation, which enables companies to store data, access accurate customer and prospect information, track leads and progress, forecast opportunities, and collaborate around any sale on desktop and mobile devices; Service Cloud that enables companies to connect address customers service and support needs; and Marketing Cloud, which enables companies to map customer journeys to digital marketing interactions through email, mobile, social, Web, and connected products.
Mylan NV (NASDAQ:MYL)’s shares dropped -1.42% to $72.28.
Mylan NV (MYL) declared the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets USP, 0.01 mg, which is the generic version of Teva’s Seasonique® Tablets. Mylan’s partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1)
Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets USP, 0.01 mg, had U.S. sales of about $160.7 million for the 12 months ending March 31, 2015, according to IMS Health.
Presently, Mylan has 271 ANDAs pending FDA approval representing $106 billion in annual brand sales, according to IMS Health. Forty-seven of these pending ANDAs are potential first-to-file opportunities, representing $32 billion in annual brand sales, for the 12 months ending December 31, 2014, according to IMS Health.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain administration, and cardiovascular therapeutic areas.
At the end of Tuesday’s trade, Ally Financial Inc (NYSE:ALLY)‘s shares dipped -0.57% to $22.63.
Ally Financial Inc (ALLY) Chief Executive Officer Jeffrey Brown will present at the Morgan Stanley Financials Conference in New York City on Tuesday, June 9, 2015 at 9:10 a.m. ET.
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers.
GlaxoSmithKline plc (ADR) (NYSE:GSK), ended its Tuesday’s trading session with 0.20% gain, and closed at $44.24.
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline plc (ADR) (GSK). ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) declared recently that Aurobindo Pharma has presented an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States.
Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.
This submission comes less than five years after ViiV Healthcare and CHAI signed a contract to collaborate with the aim of bringing innovative formulations of medicines for the treatment and prevention of HIV/AIDS to people living with HIV in developing countries, on an affordable yet sustainable basis.
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
